23rd April 2018
Coinciding with the interest around the London Marathon, the team at John Bell & Croyden (JB & C) are taking part in an ambitious charity fundraising event to raise money and awareness for Alzheimer’s Society, their charity partner. Proving that the heat doesn’t pose a challenge for these runners in their air-conditioned store, the team have a target to run over 26.2 miles in April using a treadmill installed in front of the Wigmore Street central London store.
Robin Winfield, operations director at JB & C, said: “We have a tremendous team spirit to raise as much money as possible. In addition to being our corporate charity partner, several of the team have personal connections with the cause. I am incredibly proud of everyone for working together on a programme of fundraising activities with Alzheimer’s Society.
“Over 850,000 people in the UK are affected by dementia, a condition that will rise as the population ages. Putting our patients first is our business priority and our partnership with Alzheimer’s Society fits entirely with our belief in inspiring more positive lives, reflecting the care and respect we show to our customers and patients every day.”
Alex Johnston, sales manager at JB & C, said: “I am passionate about raising awareness and funds for Alzheimer’s Society, especially to help carers of those living with dementia. I personally struggled to find support when caring for my father who had dementia, and this led me to set up coffee mornings at JB & C for people in a similar situation. A supportive network is incredibly important to carers and the feedback I’m receiving is really positive.”
The JB & C team have several other activities planned over the coming months, including participating in the RideLondon event in July, when wholesale manager James Gray will join the Alzheimer’s Society team to ride 100 miles.
Celesio UK has been an official corporate partner with Alzheimer’s Society and Alzheimer Scotland since April 2015. Over the last three years the company has raised over £400,000, funding vital research to help understand the development of dementia.